Modulation of fibril formation by a beta-sheet breaker peptide ligand: An electrochemical approach

Bioelectrochemistry

Volumn 84, Issue , 2012, Pages 49-52

  Veloso, Anthony J ^a   Kerman, Kagan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Amyloid ; Fluorescence; Square wave voltammetry; Thioflavin T

Indexed keywords

ALZHEIMER'S DISEASE; AMYLOID FIBRIL; BETA-SHEET; CARBON STRIPS; ELECTROCHEMICAL ANALYSIS; ELECTROCHEMICAL SIGNALS; FIBRIL FORMATION; FLUORESCENCE ANALYSIS; FLUORESCENT MARKERS; IN-VITRO; LABEL FREE; MEDICAL NEEDS; PEPTIDE LIGAND; SCREEN-PRINTED; SHEET FORMATION; SQUARE WAVE VOLTAMMETRY; THIOFLAVIN T; TIME-SCALES;

GLYCOPROTEINS; LIGANDS; NEURODEGENERATIVE DISEASES; OLIGOMERS; PEPTIDES; VOLTAMMETRY;

FLUORESCENCE;

AMYLOID; AMYLOID BETA PROTEIN[1-42]; LIGAND; OLIGOMER; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; BETA SHEET; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ELECTROCHEMICAL ANALYSIS; FLUORESCENCE SPECTROSCOPY; HUMAN; IN VITRO STUDY; POTENTIOMETRY; PROTEIN INTERACTION;

AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ELECTROCHEMISTRY; HUMANS; KINETICS; LIGANDS; OLIGOPEPTIDES; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; SPECTROMETRY, FLUORESCENCE;

EID: 84155163206     PISSN: 15675394     EISSN: 1878562X     Source Type: Journal    
DOI: 10.1016/j.bioelechem.2011.08.007     Document Type: Article

References (23)

1. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
2. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
3. Hardy J., Selkoe D.J. Medicine-the amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
4. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
5. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994, 77:817-827.
6. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Gotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 1993, 13:1676-1687.
7. Tjernberg L.O., Naslund J., Lindqvist F., Johansson J., Karlstrom A.R., Thyberg J., Terenius L., Nordstedt C. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 1996, 271:8545-8548.
8. Hilbich C., Kisterswoike B., Reed J., Masters C.L., Beyreuther K. Substitutions of hydrophobic amino-acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J. Mol. Biol. 1992, 228:460-473.
9. Jarrett J.T., Berger E.P., Lansbury P.T. The carboxy terminus of the beta-amyloid protein is critical for the seeding of amyloid formation-implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32:4693-4697.
10. Soto C., Castano E.M., Frangione B., Inestrosa N.C. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J. Biol. Chem. 1995, 270:3063-3067.
11. Hetenyi C., Szabo Z., Klement T., Datki Z., Kortvelyesi T., Zarandi M., Penke B. Pentapeptide amides interfere with the aggregation of beta-amyloid peptide of Alzheimer's disease. Biochem. Biophys. Res. Commun. 2002, 292:931-936.
12. Kwak J.-W., Kim H.-K., Chae C.-B. Potential lead for an Alzheimer drug: a peptide that blocks intermolecular interaction and amyloid beta protein-induced cytotoxicity. J. Med. Chem. 2006, 49:4813-4817.
13. Soto C., Kindy M.S., Baumann M., Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem. Biophys. Res. Commun. 1996, 226:672-680.
14. Adessi C., Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 2002, 9:963-978.
15. Adessi C., Frossard M.J., Boissard C., Fraga S., Bieler S., Ruckle T., Vilbois F., Robinson S.M., Mutter M., Banks W.A., Soto C. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J. Biol. Chem. 2003, 278:13905-13911.
16. Estrada L.D., Soto C. Inhibition of protein misfolding and aggregation by small rationally-designed peptides. Curr. Pharm. Des. 2006, 12:2557-2567.
17. Rocha S., Cardoso I., Borner H., Pereira M.C., Saraiva M.J., Coelho M. Design and biological activity of β-sheet breaker peptide conjugates. Biochem. Biophys. Res. Commun. 2009, 380:397-401.
18. Vestergaard M., Kerman K., Saito M., Nagatani N., Takamura Y., Tamiya E. A rapid label-free electrochemical detection and kinetic study of Alzheimer's amyloid beta aggregation. J. Am. Chem. Soc. 2005, 127:11892-11893.
19. Chikae M., Fukuda T., Kerman K., Idegami K., Miura Y., Tamiya E. Amyloid-beta detection with saccharide immobilized gold nanoparticle on carbon electrode. Bioelectrochemistry 2008, 74:118-123.
20. Veloso A.J., Hung V.W.S., Sindhu G., Constantinof A., Kerman K. Electrochemical oxidation of benzothiazole dyes for monitoring amyloid formation related to the Alzheimer's disease. Anal. Chem. 2009, 81:9410-9415.
21. Naiki H., Gejyo F. Kinetic analysis of amyloid fibril formation. Methods Enzymol. 1999, 309:305-318.
22. Soto C., Sigurdsson E., Morelli L., Kumar R., Castano E., Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 1998, 4:822-826.
23. Giuffrida M.L., Caraci F., De Bona P., Pappalardo G., Nicoletti F., Rizzarelli E., Copani A. The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. Rev. Neurosci. 2010, 21:83-93.